BHVN insider transaction filings
Biohaven Ltd. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-17. Screen BHVN transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Gentile Kimberly — SVP, Clinical Operations | 1 | — | — | 1 |
Recent Form 4 filings — Biohaven Ltd.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Gentile Kimberly — SVP, Clinical Operations | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Antonijevic Irina — Director | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Mehta Kishan — Director | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Heffernan Michael Thomas — Director | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Bailey Gregory — Director | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | HUGIN ROBERT J — Director | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | GREGORY JULIA P — Director | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | CHILDS JOHN W — Director | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Mehta Kishan — Director | Gift (G): 17,342 @ $0 · Gift (G): 17,342 @ $0 | EDGAR |
| 2026-03-09 | 4/A | CHILDS JOHN W — Director | Purchase (P): 28,400 @ $30.43 | EDGAR |
| 2026-03-03 | 4 | Buten Matthew — Chief Financial Officer | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Clark George C. — VP, Chief Accounting Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Car Bruce — Chief Scientific Officer | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Coric Vlad — Chief Executive Officer, Director | Grant/award (A): 550,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Gentile Kimberly — SVP, Clinical Operations | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Buten Matthew — Chief Financial Officer | Option exercise (M): 4,250 @ $0 · Tax withholding (F): 2,594 @ $9.93 · Option exercise (M): 4,250 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Clark George C. — VP, Chief Accounting Officer | Option exercise (M): 2,500 @ $0 · Tax withholding (F): 1,117 @ $9.93 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Car Bruce — Chief Scientific Officer | Option exercise (M): 4,750 @ $0 · Tax withholding (F): 2,381 @ $9.93 · Option exercise (M): 4,750 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Coric Vlad — Chief Executive Officer, Director | Option exercise (M): 14,250 @ $0 · Tax withholding (F): 7,430 @ $9.93 · Option exercise (M): 14,250 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Gentile Kimberly — SVP, Clinical Operations | Option exercise (M): 3,750 @ $0 · Tax withholding (F): 1,956 @ $9.93 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Clark George C. — VP, Chief Accounting Officer | Purchase (P): 17,000 @ $8.52 | EDGAR |
| 2025-11-17 | 4 | Coric Vlad — Chief Executive Officer, Director | Purchase (P): 333,333 @ $7.50 · Purchase (P): 333,333 @ $7.50 | EDGAR |
| 2025-11-17 | 4 | Bailey Gregory — Director | Purchase (P): 400,000 @ $7.50 | EDGAR |
| 2025-11-17 | 4 | CHILDS JOHN W — Director | Purchase (P): 3,333,333 @ $7.50 | EDGAR |
| 2025-05-07 | 4 | Antonijevic Irina — Director | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | Mehta Kishan — Director | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | Heffernan Michael Thomas — Director | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | Bailey Gregory — Director | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | HUGIN ROBERT J — Director | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | GREGORY JULIA P — Director | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | CHILDS JOHN W — Director | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | CHILDS JOHN W — Director | Purchase (P): 25,000 @ $30.39 · Purchase (P): 3,400 @ $30.73 · Purchase (P): 3,400 @ $30.73 · Purchase (P): 900 @ $30.73 | EDGAR |
| 2025-03-05 | 4/A | CHILDS JOHN W — Director | Purchase (P): 73,170 @ $41 | EDGAR |
| 2025-01-07 | 4 | Buten Matthew — Chief Financial Officer | Option exercise (M): 4,250 @ $0 · Tax withholding (F): 2,561 @ $38.64 · Grant/award (A): 104,000 (derivative) @ $0 · Grant/award (A): 17,000 (derivative) @ $0 · Option exercise (M): 4,250 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Clark George C. — VP, Chief Accounting Officer | Option exercise (M): 2,500 @ $0 · Tax withholding (F): 1,117 @ $38.64 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Car Bruce — Chief Scientific Officer | Option exercise (M): 4,750 @ $0 · Tax withholding (F): 2,331 @ $38.64 · Grant/award (A): 112,000 (derivative) @ $0 · Grant/award (A): 19,000 (derivative) @ $0 · Option exercise (M): 4,750 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Coric Vlad — Chief Executive Officer, Director | Option exercise (M): 14,250 @ $0 · Tax withholding (F): 6,805 @ $38.64 · Grant/award (A): 343,000 (derivative) @ $0 · Grant/award (A): 57,000 (derivative) @ $0 · Option exercise (M): 14,250 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Gentile Kimberly — SVP, Clinical Operations | Option exercise (M): 3,750 @ $0 · Tax withholding (F): 1,956 @ $38.64 · Grant/award (A): 91,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2024-12-31 | 4 | CHILDS JOHN W — Director | Purchase (P): 29,000 @ $35.94 | EDGAR |
| 2024-10-03 | 4 | Coric Vlad — Chief Executive Officer, Director | Purchase (P): 21,052 @ $47.50 | EDGAR |
| 2024-10-03 | 4 | CHILDS JOHN W — Director | Purchase (P): 21,052 @ $47.50 | EDGAR |
| 2024-09-25 | 4 | Bailey Gregory — Director | Purchase (P): 5,000 @ $44.19 | EDGAR |
| 2024-07-19 | 4 | CHILDS JOHN W — Director | Purchase (P): 28,400 @ $35.67 | EDGAR |
| 2024-06-20 | 4 | Car Bruce — Chief Scientific Officer | Purchase (P): 30,000 @ $33.58 | EDGAR |
| 2024-05-31 | 4 | CHILDS JOHN W — Director | Purchase (P): 28,000 @ $35.58 | EDGAR |
| 2024-05-15 | 4 | Bailey Gregory — Director | Purchase (P): 15,000 @ $34.19 | EDGAR |
| 2024-05-14 | 4 | CHILDS JOHN W — Director | Purchase (P): 28,500 @ $35.17 | EDGAR |
| 2024-05-02 | 4 | HUGIN ROBERT J — Director | Grant/award (A): 16,592 (derivative) @ $0 | EDGAR |
| 2024-05-02 | 4 | GREGORY JULIA P — Director | Grant/award (A): 16,592 (derivative) @ $0 | EDGAR |
| 2024-05-02 | 4 | CHILDS JOHN W — Director | Grant/award (A): 16,592 (derivative) @ $0 | EDGAR |
Recent 8-K events — Biohaven Ltd.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-10 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BHVN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →